National Cancer Institute, Acquisition Management Branch, TBS, 6120 Executive Blvd, EPS/Rm 603 Bethesda, MD 20892-7220

A -- DETAILED DRUG EVALUATION & DEVELOPMENT OF TREATMENT STRATEGIES FOR CHEMOTHERAPEUTIC AGENTS SOL N01-CM-07002-19 POC Diane Stalder; 301, 435-3813; Contract Specialist WEB: Reasearch Contracts and Acquisition Branch, http://amb.nci.nih.gov/rfp.htm. E-MAIL: Diane Stalder, ds88b@nih.gov. ELECTRONIC RFP ANNOUNCEMENT, POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. The Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), is seeking a Contractor to evaluate compounds for anticancer activity in experimental in vitro tumor models. Studies will focus on agents identified by the Program's disease-oriented in vitro drug screen and will employ human tumors growing in immune-deficient (e.g., athymic, SCID) mice. Experiments will be designed and conducted to optimize drug activity and evaluate the drug's therapeutic potential. Some in vivo studies may involve murine tumors growing in pathogen-free immune-competent mice and rats, and some cell culture support will be required for propagation of selected human tumors. Results from the project will be interrelated with pharmacokinetic, toxicologic, biochemical and immunologic information to devise and recommend treatmentstrategies for clinical trial and will be included in Investigational New Drug Applications. Compounds to be studied will be selected and assigned by the Government. As compounds of a commercially confidential nature may be evaluated, pharmaceutical and chemical companies will be excluded from the competition. Also, since structural formulae of confidential materials may be provided by the Government on occasion, the organization must be willing to sign a confidentiality of information statement. The organization shall provide facilities for handling pathogen-free immune-competent and immune-deficient mice and rats and utilize methods to protect facilities from pathogenic organisms. The Contractor also shall provide facilities/equipment for frozen storage of tumors, tumor transplantation, drug preparation, and treatment; facilities/equipment for the handling of potentially carcinogenic or hazardous materials; facilities/equipment for propagation and testing human and murine tumor lines in vitro. The Principal Investigator should have a M.D., D.V.M. or Ph.D., or equivalent degree, in one of the relevant biological sciences, should have managerial experience and experience either in managing an in vivo screening program utilizing mice and rats or in evaluating the efficacy or toxicity of antitumor agents, should understand the principles of cancer chemotherapy and should devote approximately 25% of his/her time to the project. It is anticipated that one incrementally funded contract will be awarded, for a period of three years with two one-year options. Each increment will be for a period of one year. The contract will be written on a "level of effort" basis specifying that the Contractor is to furnish 74,600 labor hours if all options are exercised. The anticipated solicitation issue date is approximately 15 days after publication of this notice, and proposals will be due approximately 45 days after the issue date. The RFP may be accessed through the Reasearch Contracts and Acquisition Branch home page by using the following Internet address: http://amb.nci.nih.gov/rfp.htm. IT IS THE OFFERORS RESPONSIBILITY TO MONITOR THE ABOVE INTERNET SITE FOR RELEASE OF THE SOLICITATION AND ANY AMENDMENTS. Point of contact is Diane Stalder, electronic mail address: ds88b@nih.gov; fax 301-402-6699. No collect calls will be accepted. Posted 05/18/99 (W-SN332787). (0138)

Loren Data Corp. http://www.ld.com (SYN# 0003 19990520\A-0003.SOL)